ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1088

Unsupervised characterization of immune checkpoint inhibitor induced inflammatory arthritis using cluster and latent class analysis: result from a multicenter prospective registry
Abstract Number: 0543

Unveiling Sacroiliac Joint Involvement in Psoriatic Arthritis: MRI, Radiographic, and Clinical Insights from 581 European Routine Care Patients
Abstract Number: 2474

Unveiling the clinical spectrum of ACA-positive SSc-ILD: not as benign as expected
Abstract Number: 1529

Updated Phase 1 Trial Data Assessing the Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-directed Chimeric Antigen Receptor T Cell Therapy Using a Next-Generation Process for Severe, Refractory SLE
Abstract Number: 2304

Updates in the local treatments in Primary Sjögren’s Syndrome “Efficacy and Safety”
Abstract Number: 1345

Upregulated TLR Signaling Identified in Difficult-to-Treat RA: A Propensity Score–Matched Transcriptome Study
Abstract Number: 1480

Urinary Biomarkers Detect Proliferative Lupus Nephritis in SLE Patients with Subclinical Proteinuria.
Abstract Number: 1750

Urinary Proteomic Signature Identifies Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
Abstract Number: 0851

Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis
Abstract Number: 0302

Urine Kynurenine Pathway Biomarkers Correlate with Disease Activity and Damage Core Set Measures in JDM
Abstract Number: 1356

Use of (MSB11456), the first tocilizumab biosimilar approved for rheumatoid arthritis: 6-month data from an international observational study
Abstract Number: 0686

Use of a Smartphone App which Incorporates Feedback to Patients to Monitor Systemic Sclerosis-related Digital Ulcers – a Potential New Tool for Remote Clinical Monitoring
Abstract Number: 0234

Use of Corneal Confocal Microscopy to Assess Small Fiber Neuropathy in Patients with Sarcoidosis
Abstract Number: 1598

Use of JAK Inhibitors in Medium- and Small-Sized Vasculitides: a Retrospective Multicenter Study
Abstract Number: 1618

Use of JAK inhibitors in patients with refractory Takayasu arteritis: A worldwide retrospective study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].